LeonaBio Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 19

Employees

  • Stock Symbol
  • LONA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.60
  • (As of Wednesday Closing)

LeonaBio General Information

Description

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

Contact Information

Formerly Known As
M3 Biotechnology, Athira, Athira Pharma
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 18706 North Creek Parkway
  • Suite 104
  • Bothell, WA 98011
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 18706 North Creek Parkway
  • Suite 104
  • Bothell, WA 98011
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LeonaBio Stock Performance

As of 18-Nov-2026, LeonaBio’s stock price is $2.60. Its current market cap is $34.7M with 13.1M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.60 $2.76 $2.21 - $14.21 $34.7M 13.1M 193K -$22.20

LeonaBio Financials Summary

As of 30-Sep-2026, LeonaBio has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (16,855) 46,090 (44,855) (78,803)
Revenue 0 0 0 0
EBITDA (155,087) (104,637) (95,970) (116,703)
Net Income (156,008) (105,609) (96,940) (117,672)
Total Assets 38,136 92,151 58,779 160,245
Total Debt 460 803 1,217 1,585
Public Fundamental Data provided by Morningstar, Inc. disclaimer

LeonaBio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore LeonaBio‘s full profile, request access.

Request a free trial

LeonaBio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore LeonaBio‘s full profile, request access.

Request a free trial

LeonaBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unm
Drug Discovery
Bothell, WA
19 As of 2025

Austin, TX
 

Lighthouse Point, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

LeonaBio Competitors (14)

One of LeonaBio’s 14 competitors is Filana Therapeutics, a Formerly VC-backed company based in Austin, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Filana Therapeutics Formerly VC-backed Austin, TX
ZyVersa Therapeutics Formerly VC-backed Lighthouse Point, FL
Alzheon Venture Capital-Backed Framingham, MA
Alector Formerly VC-backed South San Francisco, CA
AB Science Formerly Accelerator/Incubator backed Paris, France
You’re viewing 5 of 14 competitors. Get the full list »

LeonaBio Patents

LeonaBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026060341-A1 Modulators of pannexin-1 activity Pending 16-Sep-2024
WO-2025189066-A1 Modulators of g protein-coupled receptor 55 (gpr55) Pending 08-Mar-2024
WO-2025189066-A8 Modulators of g protein-coupled receptor 55 (gpr55) Pending 08-Mar-2024
JP-2025538382-A Methods for treating inflammatory conditions Pending 18-Nov-2022
AU-2023383348-A1 Methods of treating inflammatory conditions Pending 18-Nov-2022 A61K31/519
To view LeonaBio’s complete patent history, request access »

LeonaBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LeonaBio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore LeonaBio‘s full profile, request access.

Request a free trial

LeonaBio Investments (1)

LeonaBio’s most recent deal was a Corporate Asset Purchase with Sermonix Pharmaceuticals (Rights for the Development and Commercialization of Lasofoxifene). The deal was made on 18-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sermonix Pharmaceuticals (Rights for the Development and Commercialization of Lasofoxifene) 18-Dec-2025 Corporate Asset Purchase Buildings and Property
To view LeonaBio’s complete investments history, request access »

LeonaBio ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.32 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view LeonaBio’s complete esg history, request access »

LeonaBio FAQs

  • When was LeonaBio founded?

    LeonaBio was founded in 2011.

  • Where is LeonaBio headquartered?

    LeonaBio is headquartered in Bothell, WA.

  • What is the size of LeonaBio?

    LeonaBio has 19 total employees.

  • What industry is LeonaBio in?

    LeonaBio’s primary industry is Drug Discovery.

  • Is LeonaBio a private or public company?

    LeonaBio is a Public company.

  • What is LeonaBio’s stock symbol?

    The ticker symbol for LeonaBio is LONA.

  • What is the current stock price of LeonaBio?

    As of 18-Nov-2026 the stock price of LeonaBio is $2.60.

  • What is the current market cap of LeonaBio?

    The current market capitalization of LeonaBio is $34.7M.

  • Who are LeonaBio’s competitors?

    Filana Therapeutics, ZyVersa Therapeutics, Alzheon, Alector, and AB Science are some of the 14 competitors of LeonaBio.

  • What is LeonaBio’s annual earnings per share (EPS)?

    LeonaBio’s EPS for 12 months was -$22.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process